INTS Research | Milton Maxwell

INTS

Intensity Therapeutics, Inc.

0.4395

+0.0153+3.61%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

26.40M

P/E (TTM)

Basic EPS (TTM)

-0.55

Dividend Yield

Recent Filings

8-K

12/5/25Dec 5, 2025

8-K

12/4/25Dec 4, 2025

8-K

Intensity prices $4M stock offering

10/31/25Oct 31, 2025

Intensity Therapeutics announced a registered direct offering on October 30, 2025, selling 5 million shares at $0.80 each to an institutional investor for $4 million gross proceeds, closing around November 3. The funds will advance clinical trials like the Phase 3 INVINCIBLE-3 in sarcomas, extending cash runway to Q1 2027. Yet dilution looms for shareholders. This bolsters biotech funding amid tight markets.

8-K

Stockholders approve reverse split

10/23/25Oct 23, 2025

Intensity Therapeutics stockholders approved a reverse stock split on October 22, 2025, authorizing a ratio between 1-for-5 and 1-for-30, with the board deciding the exact split and option to abandon it. The vote passed overwhelmingly, with 18.3 million shares in favor versus 4.5 million against, at a special meeting where 46.61% of shares were represented. This move aims to boost share price for Nasdaq compliance. Board flexibility ensures adaptability to market conditions.

8-K

pCR in INVINCIBLE-4 Cohort A

9/10/25Sep 10, 2025

Intensity Therapeutics announced on September 10, 2025, that the first patient in Cohort A of its INVINCIBLE-4 study achieved a pathological complete response after two doses of INT230-6 followed by standard immunochemotherapy. The safety profile remains favorable so far. Yet enrollment paused due to localized skin irritation near tumors. Adjustments underway to resume dosing.

About

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

CEO

Mr. Lewis H. Bender M.A., M.B.A., M.S.

IPO

6/30/2023

Website

https://www.intensitytherapeutics.com

Employees

Sector

Healthcare

Industry

Biotechnology